From July 11, 2018, to December 27, 2023, a total of 66 patients were enrolled, including 26 with SDH-deficient GISTs, 33 with non-SDH-deficient GISTs, 6 with paragangliomas, and 1 with pancreatic cancer (Fig. 1). This evidence concerns the gene SDHB and paraganglioma.